tiprankstipranks
Trending News
More News >
MDxHealth (MDXH)
NASDAQ:MDXH

MDxHealth (MDXH) AI Stock Analysis

Compare
161 Followers

Top Page

MD

MDxHealth

(NASDAQ:MDXH)

Rating:57Neutral
Price Target:
$2.50
▲(13.12%Upside)
MDxHealth's strong revenue growth and market momentum are significant positives, driven by robust performance in prostate cancer diagnostics. However, financial instability due to high leverage, negative profitability, and valuation challenges temper the overall score.
Positive Factors
Profitability Outlook
MDXH is on track to achieve its AEBITDA positivity milestone, which is critical to de-risking the model further.
Revenue Growth
MDXH turned in a strong Q1, driving +22% Y/Y organic revenue growth on the back of +41% Y/Y volume growth from its tissue-based tests and +9% Y/Y volume growth from its liquid-based test portfolio.
Valuation Potential
Shares of MDXH trade at just 0.8x our 2026 rev estimate of $128M, below small cap peers at 2.0x, and MDXH is primed to achieve multiple expansion.
Negative Factors
Margin Pressure
Gross margin of 62.7% declined Y/Y due to timing and test mix, and expanded ~150bp Q/Q.
Valuation Concerns
The price target was adjusted from $7.00 to $5.00, indicating a more conservative outlook.

MDxHealth (MDXH) vs. SPDR S&P 500 ETF (SPY)

MDxHealth Business Overview & Revenue Model

Company DescriptionMDxHealth (MDXH) is a molecular diagnostics company focused on the development and commercialization of advanced epigenetic and other molecular diagnostic tests for cancer detection and diagnosis. Operating primarily in the healthcare sector, MDxHealth's core products include non-invasive tests for prostate and bladder cancer, which aid in the early detection and treatment of these diseases. The company's tests are designed to provide more accurate diagnosis, reduce unnecessary procedures, and contribute to personalized patient care.
How the Company Makes MoneyMDxHealth generates revenue through the sale of its proprietary diagnostic tests to healthcare providers, hospitals, laboratories, and clinicians. The company's key revenue streams include direct sales of its tests, partnerships with clinical laboratories for test processing, and collaborations with pharmaceutical companies to integrate its diagnostic solutions into broader treatment plans. MDxHealth also benefits from reimbursements provided by health insurance companies and government healthcare programs, which cover the use of its tests in clinical practice. Additionally, the company engages in research collaborations and licensing agreements that contribute to its revenue.

MDxHealth Earnings Call Summary

Earnings Call Date:May 14, 2025
(Q1-2025)
|
% Change Since: 24.16%|
Next Earnings Date:Aug 14, 2025
Earnings Call Sentiment Positive
The earnings call reflects a strong performance by MDxHealth, with consistent revenue growth driven by tissue-based tests and improved gross margins. However, challenges remain with increased net loss and the impact of a significant earn-out payment. Overall, the company's strategic positioning and future outlook appear positive, but financial losses present ongoing challenges.
Q1-2025 Updates
Positive Updates
Consistent Revenue Growth
Achieved 16th consecutive quarter of 20% or greater revenue growth, with Q1 2025 revenue growth at 22%.
Strong Tissue-Based Test Performance
Tissue-based test volume grew 41% for the quarter, indicating significant market penetration and acceptance.
Improved Gross Profit and Margin
Gross profit increased 29% to $15.5 million, with gross margins rising to 63.8% from 60.8% in Q1 2024.
Positive Adjusted EBITDA Trend
Adjusted EBITDA improved by 71% to negative $1.3 million, with expectations to achieve positive adjusted EBITDA in Q2 2025.
Strategic Positioning in Prostate Cancer Diagnostics
MDxHealth positioned as a leader with proprietary tests like Confirm and GPS, capturing a significant portion of a $500 million market opportunity.
Negative Updates
Increased Net Loss
Net loss increased by 8% to $9.2 million, primarily due to non-cash fair value adjustments.
Operating Loss Despite Revenue Growth
Operating loss for the quarter was $4.6 million, though improved from the prior year.
Impact of Earn-Out Payment
Pro forma cash balance reduced to $37.7 million after a $28 million earn-out payment to Exact Sciences.
Company Guidance
During the MDxHealth First Quarter 2025 Earnings Conference Call, the company reaffirmed its financial guidance, projecting revenue between $108 million to $110 million for the fiscal year of 2025, aligning with their objective of 20% revenue growth. The call highlighted a 22% increase in Q1 revenue to $24.3 million and a 41% growth in tissue-based test volumes. Total billable volumes reached approximately 24,000 tests, up 24% from the previous year. The company emphasized its strong market position in precision diagnostics for prostate cancer, driven by successful integration and adoption of their Confirm mdx and GPS tests, which accounted for 85% of Q1 revenue. MDxHealth also reported a gross margin increase to 63.8% and expected to achieve positive adjusted EBITDA in Q2 2025, showcasing operational discipline and sustained growth across their urology diagnostic offerings.

MDxHealth Financial Statement Overview

Summary
MDxHealth shows significant revenue growth in a high-potential industry but faces challenges with profitability, leverage, and cash flow. The high debt-to-equity ratio and negative cash flow highlight financial instability, requiring strategic debt management and improved profitability.
Income Statement
42
Neutral
MDxHealth's revenue has shown a strong upward trend with significant growth in recent years. However, the company continues to face challenges with profitability, as indicated by negative EBIT and net income. Despite the increase in gross profit, the net profit margin remains negative, reflecting ongoing financial pressure.
Balance Sheet
35
Negative
The balance sheet indicates a high level of debt relative to equity, leading to a concerning debt-to-equity ratio. The equity ratio is low, showing limited shareholder equity in comparison to total assets. These factors suggest a leveraged position, which can pose financial risks if not managed carefully.
Cash Flow
40
Negative
While MDxHealth's free cash flow remains negative, there is an improvement in cash flow from financing activities. The operating cash flow continues to be negative, indicating challenges in generating cash from operations. The company shows some resilience through financing activities, but sustained negative free cash flow is a concern.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue94.51M90.05M70.19M37.05M22.24M18.37M
Gross Profit58.58M55.14M43.93M19.22M10.41M7.85M
EBITDA-13.43M-21.70M-30.47M-36.39M-23.99M-23.79M
Net Income-38.77M-38.07M-43.10M-50.19M-30.88M-30.01M
Balance Sheet
Total Assets174.83M157.33M129.13M119.14M75.07M31.86M
Cash, Cash Equivalents and Short-Term Investments65.67M46.80M22.38M15.50M58.50M15.95M
Total Debt83.98M60.06M41.27M39.79M15.56M15.87M
Total Liabilities168.87M142.49M121.92M109.82M28.17M26.01M
Stockholders Equity5.97M14.84M7.21M9.31M46.90M5.85M
Cash Flow
Free Cash Flow-17.52M-19.72M-26.52M-38.28M-23.44M-20.78M
Operating Cash Flow-15.65M-18.53M-21.50M-34.12M-22.55M-20.24M
Investing Cash Flow-1.00M-1.64M-3.93M-29.16M-885.00K-537.00K
Financing Cash Flow67.84M44.60M32.28M20.84M66.50M14.29M

MDxHealth Technical Analysis

Technical Analysis Sentiment
Positive
Last Price2.21
Price Trends
50DMA
1.99
Positive
100DMA
1.81
Positive
200DMA
1.95
Positive
Market Momentum
MACD
0.06
Negative
RSI
56.48
Neutral
STOCH
66.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MDXH, the sentiment is Positive. The current price of 2.21 is above the 20-day moving average (MA) of 2.12, above the 50-day MA of 1.99, and above the 200-day MA of 1.95, indicating a bullish trend. The MACD of 0.06 indicates Negative momentum. The RSI at 56.48 is Neutral, neither overbought nor oversold. The STOCH value of 66.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MDXH.

MDxHealth Risk Analysis

MDxHealth disclosed 57 risk factors in its most recent earnings report. MDxHealth reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

MDxHealth Peers Comparison

Overall Rating
UnderperformOutperform
Sector (46)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
XGXGN
62
Neutral
$152.81M-117.50%1.78%22.46%
57
Neutral
$109.29M-1552.23%25.46%21.83%
PRPRE
54
Neutral
$103.10M-26.74%85.33%30.70%
52
Neutral
$77.42M138.92%64.15%41.65%
52
Neutral
$92.30M-41.36%-44.17%12.77%
46
Neutral
C$194.85M-4.28-8.56%2.84%13.52%-1.74%
43
Neutral
$40.30M-1454.41%35.76%47.48%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
MDXH
MDxHealth
2.21
-0.13
-5.56%
VNRX
VolitionRX
0.75
0.13
20.97%
XGN
Exagen
6.97
5.23
300.57%
BDSX
Biodesix
0.28
-1.29
-82.17%
PRE
Prenetics Group
7.91
1.93
32.27%
SERA
Sera Prognostics
2.45
-2.94
-54.55%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 28, 2025